SAGE Therapeutics (SAGE) Tops Q1 EPS by 4c

SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($2.46), $0.04 better than the analyst estimate of ($2.50). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $2.41 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Data storage group MongoDB delivers upbeat guidance after Q3 results top estimates
• Yext, Inc. (YEXT) plunges as revenue misses expectations, full-year sales guidance cut
• Box (BOX) Misses Q3 EPS by 2c; offers outlook